Overview
Editas Medicine is developing CRISPR genome editing medicines for ocular, hematologic, and oncologic diseases. Tailored for modern biology and life science teams.
Key Highlights
- In vivo CRISPR trial EDIT-101 targeting LCA10 inherited blindness.
- Allogeneic CAR-T programs leveraging CRISPR for next-gen immunotherapy.
- Manufacturing partnerships delivering clinical-grade editing.
Ideal For
- Clinicians monitoring ophthalmology and oncology gene editing
- Biotech investors tracking CRISPR clinical progress
- Researchers collaborating on CRISPR-based therapies
Quick Links
- Official site: editasmedicine.com
- Add to BioDir collections to track updates and collaborators.